Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › pazopanib

pazopanib

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of pazopanib

63 trials tracked of pazopanib: 9 in phase 3 or 4 and 2 with published results. The most-cited published study has 66 citations.

63Trials tracked
9Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 1 Phase 3 8 Phase 2 48 Phase 1 5 Other / NA 1
  1. Phase 3 A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) Completed · 66 cited
  2. Phase 3 Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) Completed · 19 cited
  3. Phase 4 VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK Completed
  4. Phase 3 Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma Completed
  5. Phase 3 Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer Completed
  6. Phase 3 Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer Completed
Show 44 more trials
  1. Phase 3 Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed
  2. Phase 3 Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma Completed
  3. Phase 3 Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed
  4. Phase 2 Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas Completed
  5. Phase 2 Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women Completed
  6. Phase 2 Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab Completed
  7. Phase 2 Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib Completed
  8. Phase 2 Pazopanib in Treating Patients With Recurrent Glioblastoma Completed
  9. Phase 2 Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma Completed
  10. Phase 2 Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma Completed
  11. Phase 2 Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) Completed
  12. Phase 2 Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Completed
  13. Phase 2 Pazopanib as Single Agent in Advanced NETs Completed
  14. Phase 2 A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection Completed
  15. Phase 2 Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery Completed
  16. Phase 2 Pazopanib in Treating Patients With Malignant Pleural Mesothelioma Completed
  17. Phase 2 Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer Completed
  18. Phase 2 A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer Completed
  19. Phase 2 Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer Completed
  20. Phase 2 Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer Completed
  21. Phase 2 Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer Completed
  22. Phase 2 Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer Completed
  23. Phase 2 Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery Completed
  24. Phase 2 Neoadjuvant Pazopanib in Renal Cell Carcinoma Completed
  25. Phase 2 Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer Completed
  26. Phase 2 Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer Completed
  27. Phase 2 Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer Completed
  28. Phase 2 Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy Completed
  29. Phase 2 Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome Completed
  30. Phase 2 Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma Completed
  31. Phase 2 Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment Completed
  32. Phase 2 Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer Completed
  33. Phase 2 To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD Completed
  34. Phase 2 Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma Completed
  35. Phase 2 Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer Completed
  36. Phase 2 Pazopanib in Treating Patients With Metastatic Urothelial Cancer Completed
  37. Phase 2 Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Completed
  38. Phase 2 An Extension to Study MD7108240 Completed
  39. Phase 2 Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma Completed
  40. Phase 2 Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab Completed
  41. Phase 2 Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer Completed
  42. Phase 2 Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial Completed
  43. Phase 2 Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer Completed
  44. Phase 2 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed

Showing the 50 most-cited and recently-updated of 63 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Protocol for a systematic review and network meta-analysis of second-line soft tissue sarcoma treatments
Oncology Meta-analysis
Protocol for a systematic review and network meta-analysis of second-line soft tissue sarcoma treatments Protocol outlines options for second-line soft tissue sarcoma treatments
This is a protocol for a systematic review and network meta-analysis. It will evaluate second-line pharmacological regimens for advanced sof…
A new protocol maps second-line drug choices for advanced soft tissue sarcoma patients previously treated with anthracyclines, noting curren…
medRxiv May 24, 2026